Samsung Bioepis Snags Second EU Denosumab Biosimilar – But More Are On The Way

Rivals To Prolia And Xgeva Receive Endorsement From EMA’s CHMP

 
• By Dave Wallace
  
More rivals are lining up behind Samsung Bioepis and Sandoz (Shutterstock)

More from Biosimilars

More from Generics Bulletin